Filtered By:
Therapy: Immunotherapy
This page shows you your search results in order of date. This is page number 7.
Order by Relevance | Date
Total 258 results found since Jan 2013.
Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches
CONCLUSION: Our findings suggest a potential combination approach for cancer immunotherapy using PLGA (PD-L1 siRNA+PD-1 siRNA)-NPs and PLGA (antigen+adjuvant)-NPs as novel immune checkpoint silencing agents.PMID:35228265 | DOI:10.1136/jitc-2021-003928
Source: Cancer Control - March 1, 2022 Category: Cancer & Oncology Authors: Ji Eun Won Youngseon Byeon Tae In Wi Chan Mi Lee Ju Hyeong Lee Tae Heung Kang Jeong-Won Lee YoungJoo Lee Yeong-Min Park Hee Dong Han Source Type: research
Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response
CONCLUSIONS: These findings suggest that the use of new nanocarriers such as SPION-C-CMD-FA could be an effective way to use as a novel combination therapy consisting of β-catenin siRNA, IL-15, and DC vaccine to treat cancer.PMID:35166995 | DOI:10.1007/s11095-022-03169-2
Source: Cell Research - February 15, 2022 Category: Cytology Authors: Armin Mahmoud Salehi Kheshti Farnaz Hajizadeh Asal Barshidi Bentolhoda Rashidi Farbod Ebrahimi Simin Bahmanpour Vahid Karpisheh Fatemeh Karimian Noukabadi Fariba Karoon Kiani Hadi Hassannia Fatemeh Atyabi Seyed Hossein Kiaie Fatah Kashanchi Jamshid Gholiz Source Type: research
High expression of CD28 enhanced the anti-cancer effect of siRNA-PD-1 through prompting the immune response of melanoma-bearing mice
Int Immunopharmacol. 2022 Jan 27;105:108572. doi: 10.1016/j.intimp.2022.108572. Online ahead of print.ABSTRACTImmune checkpoint blockade is considered to be an effective method of tumor immunotherapy. As one of the main immune checkpoints, blocking PD-1/PD-L1 pathway has been proved to be effective in the treatment of many cancers via activating T cells; however, many patients still do not respond to the blocking PD-1/PD-L1 treatment with satisfying results. Related research demonstrated that the activation of T cells required a co-stimulatory signal generated by the interaction between CD28 and CD80/CD86, whereas in many ...
Source: International Immunopharmacology - January 30, 2022 Category: Allergy & Immunology Authors: Huijie Jia Jing Guo Zhiang Liu Pengfei Chen Yang Li Ruipeng Li Yunfan Yang Xinyi Li Pengkun Wei Jiateng Zhong Feng Ren Mingyong Wang Jianzhuang Ren Zhiwei Feng Tiesuo Zhao Source Type: research
Exosomes derived from immunogenically dying tumor cells as a versatile tool for vaccination against pancreatic cancer
Biomaterials. 2021 Dec 2;280:121306. doi: 10.1016/j.biomaterials.2021.121306. Online ahead of print.ABSTRACTDespite tremendous progress achieved in immunotherapy, many critical challenges in treating pancreatic ductal adenocarcinoma (PDAC) persist. Considering the poor vascularization of PDAC, after intramuscular administration exosomes can targeted deliver "cargos" to pancreatic tumors and bypass obstructions of the intrinsic overexpressed stroma through lymphatics. Herein, we propose a strategy to derive exosomes from immunogenically dying tumor cells and exploit their properties for several purposes, including antigen p...
Source: Biomaterials - December 24, 2021 Category: Materials Science Authors: Wenxi Zhou Xinli Chen Yu Zhou Si Shi Chen Liang Xianjun Yu Hongyi Chen Qin Guo Yiwen Zhang Peixin Liu Chao Li Yongchao Chu Yifan Luo Yu Wang Zheng Zhou Zhenhao Zhao Qinjun Chen Tao Sun Chen Jiang Source Type: research
Epigenetic Priming of Bladder Cancer Cells With Decitabine Increases Cytotoxicity of Human EGFR and CD44v6 CAR Engineered T-Cells
CONCLUSION: Our data suggest that the combination of decitabine with CAR T-cell therapy is an attractive novel therapeutic approach to enhance tumor-specific killing of bladder cancer. Since BID and BCL2L1 are essential determinants for the susceptibility of a wide variety of malignant cells, their targeting might be additionally suitable for combination with immunotherapies, e.g., CAR T-cells or checkpoint inhibitors in other malignancies.PMID:34868059 | PMC:PMC8637820 | DOI:10.3389/fimmu.2021.782448
Source: Cancer Control - December 6, 2021 Category: Cancer & Oncology Authors: Camilla M Grunewald Corinna Haist Carolin K önig Patrick Petzsch Arthur Bister Elfriede N ößner Constanze Wiek Kathrin Scheckenbach Karl K öhrer G ünter Niegisch Helmut Hanenberg Mich èle J Hoffmann Source Type: research
PCSK9 as a new player in cancer: New opportunity or red herring?
Curr Med Chem. 2021 Nov 15. doi: 10.2174/0929867328666211115122324. Online ahead of print.ABSTRACTInitially described as a factor involved in liver regeneration and neuronal differentiation, proprotein convertase subtilisin/kexin type 9 (PCSK9) has become one of the key regulators of low-density lipoprotein cholesterol. Besides that, a number of studies have suggested PCSK9 may play a role in cancer biology. This is particularly true for gastroenteric (gastric and liver cancers) and lung cancers, where higher PCSK9 levels were associated with the increased ability of the tumor to develop and give metastasis as well as with...
Source: Current Medicinal Chemistry - November 16, 2021 Category: Chemistry Authors: Aldo Bonaventura Alessandra Vecchi é Massimiliano Ruscica Francesco Grossi Francesco Dentali Source Type: research
Developing Biodegradable Lipid Nanoparticles for Intracellular mRNA Delivery and Genome Editing
Acc Chem Res. 2021 Oct 20. doi: 10.1021/acs.accounts.1c00500. Online ahead of print.ABSTRACTConspectusSince the U.S. Food and Drug Administration (FDA) granted emergency use authorization for two mRNA vaccines against SARS-CoV-2, mRNA-based technology has attracted broad attention from the scientific community to investors. When delivered intracellularly, mRNA has the ability to produce various therapeutic proteins, enabling the treatment of a variety of illnesses, including but not limited to infectious diseases, cancers, and genetic diseases. Accordingly, mRNA holds significant therapeutic potential and provides a promis...
Source: Cell Research - October 20, 2021 Category: Cytology Authors: Min Qiu Yamin Li Hanan Bloomer Qiaobing Xu Source Type: research
Immunotherapy with a biologically active ICAM-1 mAb and an siRNA targeting TSHR in a BALB/c mouse model of Graves' disease
Conclusions These preliminary data suggest that both the biologically active ICAM-1 mAb and the siRNA targeting TSHR were effective. The ICAM-1 mAb exerted a better therapeutic effect than the siRNA targeting TSHR. Both treatments showed potential efficacy as novel treatments for GD and may therefore represent therapeutic options in addition to the existing drugs or interventions.PMID:34647608 | DOI:10.5603/EP.a2021.0087
Source: Endokrynologia Polska - October 14, 2021 Category: Endocrinology Authors: Xuan Wang Wei Liu Zhongying Rui Wei Zheng Jian Tan Ning Li Yang Yu Source Type: research
